MedTrace Logo

Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected Adults

NCT00270218 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2021-10-14

No results posted yet for this study

Summary

The purpose of this study is to determine the safety of and immune response to an adenoviral vector HIV vaccine or a DNA HIV vaccine, each followed by an adenoviral vector HIV vaccine boost, in HIV uninfected adults.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

VRC-HIVADV014-00-VP

HIV-1 recombinant adenoviral vector vaccine given as a 1 mL intramuscular injection in the deltoid

BIOLOGICAL

VRC-HIVDNA009-00-VP

HIV-1 DNA plasmid vaccine given as a 1 mL intramuscular injection in the deltoid

BIOLOGICAL

FFB

Adenoviral vector FFB given as a 1 mL intramuscular injection in the deltoid

BIOLOGICAL

PBS

phosphate buffered saline

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Stephen De Rosa, MD · Fred Hutchinson Cancer Research Center and University of Washington

  • Spyros A. Kalams, MD · Vanderbilt University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-02-28
Completion
2007-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00270218 on ClinicalTrials.gov